Evidence map›Paper›PMID 31980496›Full record

ArticleThe European respiratory journal2020

Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent.

Rachele Invernizzi, Joseph Barnett, Bhavin Rawal, Arjun Nair, Poonam Ghai, Shaun Kingston, Felix Chua, Zhe Wu, Athol U Wells, Elizabeth R Renzoni and 7 more

Open access · hybridAbstract read
In one paragraph

Article in The European respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Hallmarks of the ageing lung: 10 years later.The European respiratory journal · 2026
    Review
  8. Article
  9. Immunological mechanisms and therapeutic approaches in pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. The lung microbiome in interstitial lung disease.Breathe (Sheffield, England) · 2025
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Rachele InvernizziNational Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0002-6957-9626
Joseph BarnettNational Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0002-2795-5654
Bhavin RawalRoyal Brompton Hospital, London, UK.
Arjun NairDept of Radiology, University College Hospital, London, UK.
Poonam GhaiNational Heart and Lung Institute, Imperial College London, London, UK.
Shaun KingstonNational Heart and Lung Institute, Imperial College London, London, UK.
Felix ChuaRoyal Brompton Hospital, London, UK.
Zhe WuNational Heart and Lung Institute, Imperial College London, London, UK.
Athol U WellsRoyal Brompton Hospital, London, UK.
Elizabeth R RenzoniRoyal Brompton Hospital, London, UK.
Andrew G NicholsonNational Heart and Lung Institute, Imperial College London, London, UK.
Alexandra RiceRoyal Brompton Hospital, London, UK.
Clare M LloydNational Heart and Lung Institute, Imperial College London, London, UK.
Adam J ByrneNational Heart and Lung Institute, Imperial College London, London, UK.
Toby M MaherNational Heart and Lung Institute, Imperial College London, London, UK.
Anand DevarajNational Heart and Lung Institute, Imperial College London, London, UK.
Philip L MolyneauxNational Heart and Lung Institute, Imperial College London, London, UK p.molyneaux@imperial.ac.uk.ORCID 0000-0003-1301-8800
Royal Brompton Hospital · GBImperial College London · GBUniversity College Hospital · GB

Funding

Department of Health CS-2013-13-017HSRD VA CDA 13-017Wellcome TrustWellcome Trust 107059/Z/15/ZWellcome Trust 205949/Z/17/Z
6 · The paper itself

Abstract

Increasing bacterial burden in the lower airways of patients with idiopathic pulmonary fibrosis confers an increased risk of disease progression and mortality. However, it remains unclear whether this increased bacterial burden directly influences progression of fibrosis or simply reflects the magnitude of the underlying disease extent or severity.We prospectively recruited 193 patients who underwent bronchoscopy and received a multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Quantification of the total bacterial burden in bronchoalveolar lavage fluid was performed by 16S rRNA gene qPCR. Imaging was independently evaluated by two readers assigning quantitative scores for extent, severity and topography of radiographic changes and relationship of these features with bacterial burden was assessed.Increased bacterial burden significantly associated with disease progression (HR 2.1; 95% CI 1.287-3.474; p=0.0028). Multivariate stepwise regression demonstrated no relationship between bacterial burden and radiological features or extent of disease. When specifically considering patients with definite or probable usual interstitial pneumonia there was no difference in bacterial burden between these two groups. Despite a postulated association between pleuroparenchymal fibroelastosis and clinical infection, there was no relationship between either the presence or extent of pleuroparenchymal fibroelastosis and bacterial burden.We demonstrate that bacterial burden in the lower airways is not simply secondary to the extent of the underlying architectural destruction of the lung parenchyma seen in idiopathic pulmonary fibrosis. The independent nature of this association supports a relationship with the underlying pathogenic mechanisms and highlights the urgent need for functional studies.

Indexed as

Idiopathic Pulmonary FibrosisBronchoalveolar Lavage FluidDisease ProgressionHumansLungRNA, Ribosomal, 16SRNA, Ribosomal, 16S

Identifiers

PMID31980496
PMCPMC7136009
OpenAlexW3001732865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.